~~<i id='99B49F6A24'><strike id='99B49F6A24'><tt id='99B49F6A24'><pre id='99B49F6A24'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：hotspot 2025-09-30 22:55:02 - browse：11121

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Patients, digital health players weigh in on FTC's data privacy plan

entertainment

Wikipedia

hotspot

focus

hotspot

5:04InthisimageobtainedfromtheCountyofMauiinHawaii,showsawildfireinLahaina,onAug.9,2023.Hawaiiwildfi

WSS

BMS, looking to build heart drug business, turns to AI for diagnosis

Treatments for cramps don't cut it. Why aren't there better options?

Bird flu researchers hone in on Finland’s mink farms

Be careful with at

After Optum profits sink, UnitedHealth makes changes

'Revelatory' study finds a smoking impact that remains after quitting

focus

focus

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Idaho college killings prosecutors challenge defense's grand jury claims

Walensky prepares to leave CDC — and Congress — behind

Industry veterans launch new biotech VC with $310M

Supreme Court strikes down use of affirmative action

Gilead might be held responsible for not developing a drug

In age of alternative facts, a scholarly course on calling out crap

BioAge raises $170M for combination therapy with Zepbound

The high cost of giving birth even with insurance

Medicare Advantage proposed rates disappoint insurers

Wikipedia

Biden administration begins canceling student loan debt for 804,000 borrowers

'Revelatory' study finds a smoking impact that remains after quitting

Biogen Alzheimer’s drug launch off to slow start

KalVista pill reduced swelling 'attacks' caused by genetic disease

Montana youths win climate lawsuit against state for promoting fossil fuels

Biogen’s boardroom scandal saddles CEO with first crisis

hotspot

hotspot

focus

hotspot